C4 Therapeutics Inc Stock News

C4 Therapeutics (NASDAQ:CCCC) was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report issued on Friday, Zacks.com reports. The firm currently has a $40.00 price objective on the stock. Zacks Investment Researchs price objective points to a potential upside of 16.38% from the stocks current price. According to []

Zacks Investment Research cut shares of C4 Therapeutics (NASDAQ:CCCC) from a buy rating to a hold rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates []

Zacks Investment Research upgraded shares of C4 Therapeutics (NASDAQ:CCCC) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. The firm currently has $42.00 price objective on the stock. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the bodys natural regulation []

C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.

C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.

C4 Therapeutics (NASDAQ:CCCC) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Tuesday, Zacks.com reports. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the bodys natural regulation of protein levels to develop novel therapeutic candidates to target and []

Coherus BioSciences (NASDAQ:CHRS) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings. Analyst Recommendations This is a breakdown of current ratings for Coherus BioSciences and C4 Therapeutics, []

Several brokerages have updated their recommendations and price targets on shares of C4 Therapeutics (NASDAQ: CCCC) in the last few weeks: 11/24/2021 C4 Therapeutics was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on []

C4 Therapeutics, Inc. (NASDAQ:CCCC) has been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokers […]

Bank of America started coverage on shares of C4 Therapeutics (NASDAQ:CCCC) in a note issued to investors on Tuesday, Price Targets.com reports. The brokerage set a buy rating and a $54.00 price target on the stock. Bank of Americas price objective suggests a potential upside of 42.78% from the companys current price. A number of []

Analysts at Bank of America began coverage on shares of C4 Therapeutics (NASDAQ:CCCC) in a research note issued on Tuesday, The Fly reports. The brokerage set a buy rating on the stock. A number of other research analysts have also weighed in on CCCC. SVB Leerink began coverage on C4 Therapeutics in a research note []

C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Charles Schwab Investment Management Inc. raised its holdings in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) by 101.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,594 shares of the companys stock after buying an additional 70,882 shares during the period. Charles []

First Trust Advisors LP bought a new position in shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 22,264 shares of the companys stock, valued at approximately $842,000. Several other hedge funds have also modified their []